Evidence map›Paper›PMID 24909994›Full record

ArticleNature2014

SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma.

Soufiane Boumahdi, Gregory Driessens, Gaelle Lapouge, Sandrine Rorive, Dany Nassar, Marie Le Mercier, Benjamin Delatte, Amélie Caauwe, Sandrine Lenglez, Erwin Nkusi and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 426 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
426citing papers in PubMed, 2 pooled it
32.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

426 citing papers in PubMed, 2 syntheses or guidelines pooled it, 665 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cell plasticity in cancer and therapy resistance.Experimental & molecular medicine · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. OCT4 and NANOG are involved in adrenocortical tumorigenesis.Archives of endocrinology and metabolism · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

366 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Soufiane BoumahdiUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Gregory Driessens1] Université Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium [2].
Gaelle Lapouge1] Université Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium [2].
Sandrine Rorive1] Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium [2] DIAPATH-Center for Microscopy and Molecular Imaging (CMMI), Gosselies B-6041, Belgium.
Dany NassarUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Marie Le MercierDepartment of Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium.
Benjamin DelatteLaboratory of Cancer Epigenetics, Université Libre de Bruxelles, Brussels B-1070, Belgium.
Amélie CaauweUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Sandrine LenglezUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Erwin NkusiUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Sylvain BrohéeMachine Learning Group, Computer Science Department, Faculté des Sciences, Université Libre de Bruxelles, Brussels B-1050, Belgium.
Isabelle Salmon1] Department of Pathology, Erasme Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium [2] DIAPATH-Center for Microscopy and Molecular Imaging (CMMI), Gosselies B-6041, Belgium.
Christine DuboisUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Veronique del MarmolDepartment of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels B-1070, Belgium.
Francois FuksLaboratory of Cancer Epigenetics, Université Libre de Bruxelles, Brussels B-1070, Belgium.
Benjamin BeckUniversité Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium.
Cédric Blanpain1] Université Libre de Bruxelles, IRIBHM, Brussels B-1070, Belgium [2] WELBIO, Université Libre de Bruxelles, Brussels B-1070, Belgium.
Université Libre de Bruxelles · BEWalloon Excellence in Lifesciences and Biotechnology · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) have been reported in various cancers, including in skin squamous-cell carcinoma (SCC). The molecular mechanisms regulating tumour initiation and stemness are still poorly characterized. Here we find that Sox2, a transcription factor expressed in various types of embryonic and adult stem cells, was the most upregulated transcription factor in the CSCs of squamous skin tumours in mice. SOX2 is absent in normal epidermis but begins to be expressed in the vast majority of mouse and human pre-neoplastic skin tumours, and continues to be expressed in a heterogeneous manner in invasive mouse and human SCCs. In contrast to other SCCs, in which SOX2 is frequently genetically amplified, the expression of SOX2 in mouse and human skin SCCs is transcriptionally regulated. Conditional deletion of Sox2 in the mouse epidermis markedly decreases skin tumour formation after chemical-induced carcinogenesis. Using green fluorescent protein (GFP) as a reporter of Sox2 transcriptional expression (SOX2-GFP knock-in mice), we showed that SOX2-expressing cells in invasive SCC are greatly enriched in tumour-propagating cells, which further increase upon serial transplantations. Lineage ablation of SOX2-expressing cells within primary benign and malignant SCCs leads to tumour regression, consistent with the critical role of SOX2-expressing cells in tumour maintenance. Conditional Sox2 deletion in pre-existing skin papilloma and SCC leads to tumour regression and decreases the ability of cancer cells to be propagated upon transplantation into immunodeficient mice, supporting the essential role of SOX2 in regulating CSC functions. Transcriptional profiling of SOX2-GFP-expressing CSCs and of tumour epithelial cells upon Sox2 deletion uncovered a gene network regulated by SOX2 in primary tumour cells in vivo. Chromatin immunoprecipitation identified several direct SOX2 target genes controlling tumour stemness, survival, proliferation, adhesion, invasion and paraneoplastic syndrome. We demonstrate that SOX2, by marking and regulating the functions of skin tumour-initiating cells and CSCs, establishes a continuum between tumour initiation and progression in primary skin tumours.

Indexed as

Carcinoma, Squamous CellSkin NeoplasmsAnimalsCell AdhesionCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalGene DeletionGene Expression ProfilingGene Expression Regulation, NeoplasticGene Knockdown TechniquesGene Regulatory NetworksMiceMice, Inbred StrainsNeoplastic Stem CellsSOXB1 Transcription FactorsSox2 protein, mouseSOXB1 Transcription Factors

Identifiers

PMID24909994
OpenAlexW2111511846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.